Search

Your search keyword '"Burmester G."' showing total 1,971 results
Start Over Author "Burmester G."

Refine your results

more »

more »

more »

more »
1,971 results on '"Burmester G."'

1. POS0051 AN UPDATE ON THE INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS OVER A MEDIAN OF 4.3 YEARS

Author

Winthrop, K. L., primary, Aletaha, D., additional, Caporali, R. F., additional, Tanaka, Y., additional, Takeuchi, T., additional, Modgill, V., additional, Ekoka Omoruyi, E. V., additional, De Vries, D., additional, Van Beneden, K., additional, Gottenberg, J. E., additional, and Burmester, G. R., additional

Published
2024
Full Text
View/download PDF

4. POS0894 SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA

Author

Burmester, G. R., primary, Cohen, S. B., additional, Deodhar, A., additional, Mysler, E., additional, Rubbert-Roth, A., additional, Tanaka, Y., additional, Winthrop, K. L., additional, Nakasato, P., additional, Coombs, D., additional, Gara, A., additional, Khan, N., additional, Kovacs, B., additional, Meerwein, S., additional, and Curtis, J. R., additional

Published
2024
Full Text
View/download PDF

5. AB0027 PHARMACOKINETICS AND SAFETY OF CT-P47, A PROPOSED TOCILIZUMAB BIOSIMILAR, IN COMPARISON WITH INTRAVENOUS EU-APPROVED TOCILIZUMAB AND US-LICENSED TOCILIZUMAB; A PHASE 1, RANDOMIZED, DOUBLE-BLIND, THREE-ARM, SINGLE-DOSE STUDY IN HEALTHY JAPANESE SUBJECTS

Author

Haranaka, M., primary, Eto, T., additional, Tanaka, T., additional, Yazawa, R., additional, Burmester, G. R., additional, Keystone, E., additional, Kim, S. H., additional, Bae, Y., additional, Suh, J., additional, Kim, Y., additional, Lee, J., additional, and Smolen, J. S., additional

Published
2024
Full Text
View/download PDF

6. LBA0007 SAFETY AND EFFICACY OF DARATUMUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS – A SINGLE-CENTER PHASE 2 OPEN-LABEL TRIAL

Author

Alexander, T., primary, Ostendorf, L., additional, Zernicke, J., additional, Klotsche, J., additional, Schneider, U., additional, Biesen, R., additional, Kempkens, R., additional, Cheng, Q., additional, Khodadadi, L., additional, Heinrich, F., additional, Durek, P., additional, Burmester, G. R., additional, Mashreghi, M. F., additional, Krönke, G., additional, and Hiepe, F., additional

Published
2024
Full Text
View/download PDF

11. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

Author

Talarico, R, Ramirez, G, Barreira, S, Cardamone, C, Triggianese, P, Aguilera, S, Andersen, J, Avcin, T, Benistan, K, Bertsias, G, Bortoluzzi, A, Bouillot, C, Bulina, I, Burmester, G, Callens, S, Carreira, P, Cervera, R, Cutolo, M, Damian, L, Della-Torre, E, Faria, R, Fonseca, J, Galetti, I, Hachulla, E, Iaccarino, L, Jacobsen, S, Khmelinskii, N, Limper, M, Marinello, D, Meyer, A, Moroncini, G, Nagy, G, Olesinska, M, Pamfil, C, Pileckyte, M, Pistello, M, Rednic, S, Richez, C, Romao, V, Schneider, M, Sciascia, S, Scire, C, Simonini, G, Smith, V, Sulli, A, Tani, C, Tas, S, Tincani, A, Vonk, M, Tektonidou, M, Mosca, M, Talarico R., Ramirez G. A., Barreira S. C., Cardamone C., Triggianese P., Aguilera S., Andersen J., Avcin T., Benistan K., Bertsias G., Bortoluzzi A., Bouillot C., Bulina I., Burmester G. R., Callens S., Carreira P. E., Cervera R., Cutolo M., Damian L., Della-Torre E., Faria R., Fonseca J. E., Galetti I., Hachulla E., Iaccarino L., Jacobsen S., Khmelinskii N., Limper M., Marinello D., Meyer A., Moroncini G., Nagy G., Olesinska M., Pamfil C., Pileckyte M., Pistello M., Rednic S., Richez C., Romao V. C., Schneider M., Sciascia S., Scire C. A., Simonini G., Smith V., Sulli A., Tani C., Tas S. W., Tincani A., Vonk M. C., Tektonidou M., Mosca M., Talarico, R, Ramirez, G, Barreira, S, Cardamone, C, Triggianese, P, Aguilera, S, Andersen, J, Avcin, T, Benistan, K, Bertsias, G, Bortoluzzi, A, Bouillot, C, Bulina, I, Burmester, G, Callens, S, Carreira, P, Cervera, R, Cutolo, M, Damian, L, Della-Torre, E, Faria, R, Fonseca, J, Galetti, I, Hachulla, E, Iaccarino, L, Jacobsen, S, Khmelinskii, N, Limper, M, Marinello, D, Meyer, A, Moroncini, G, Nagy, G, Olesinska, M, Pamfil, C, Pileckyte, M, Pistello, M, Rednic, S, Richez, C, Romao, V, Schneider, M, Sciascia, S, Scire, C, Simonini, G, Smith, V, Sulli, A, Tani, C, Tas, S, Tincani, A, Vonk, M, Tektonidou, M, Mosca, M, Talarico R., Ramirez G. A., Barreira S. C., Cardamone C., Triggianese P., Aguilera S., Andersen J., Avcin T., Benistan K., Bertsias G., Bortoluzzi A., Bouillot C., Bulina I., Burmester G. R., Callens S., Carreira P. E., Cervera R., Cutolo M., Damian L., Della-Torre E., Faria R., Fonseca J. E., Galetti I., Hachulla E., Iaccarino L., Jacobsen S., Khmelinskii N., Limper M., Marinello D., Meyer A., Moroncini G., Nagy G., Olesinska M., Pamfil C., Pileckyte M., Pistello M., Rednic S., Richez C., Romao V. C., Schneider M., Sciascia S., Scire C. A., Simonini G., Smith V., Sulli A., Tani C., Tas S. W., Tincani A., Vonk M. C., Tektonidou M., and Mosca M.

Abstract

Recent studies have shown that people who are immunocompromised may inadvertently play a role in spurring the mutations of the virus that create new variants. This is because some immunocompromised individuals remain at risk of getting COVID-19 despite vaccination, experience more severe disease, are susceptible to being chronically infected and remain contagious for longer if they become infected and considering that immunocompromised individuals represent approximately 2% of the overall population, this aspect should be carefully considered. So far, some autoimmune rheumatic disease (ARD) patients with COVID-19 have been treated with antiviral therapies or anti-SARS-CoV-2 antibody products. However, there is no homogeneous approach to these treatment strategies. This issue was addressed within the European Reference Network (ERN) on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ReCONNET) in a discussion among experts and patient's representatives in the context of the rare and complex connective tissue diseases (rCTDs) covered by the Network. ERN ReCONNET is one of the 24 ERNs launched by the European Commission in 2017 with the aim of tackling low prevalence and rare diseases that require highly specialised treatment and promoting concentration of knowledge and resources through virtual networks involving healthcare providers (HCPs) across the European Union (EU). Considering the urgent need to provide guidance not only to the rCTDs community, but also to the whole ARDs community, a multidisciplinary Task Force, including expert clinicians and European Patient Advocacy Group (ePAG) Advocates, was created in the framework of ERN ReCONNET with the aim of developing overarching principles (OP) and points-to-consider (PtC) on a homogenous approach to treat immunocompromised patients with ARDs (with a particular focus on CTDs) affected by COVID-19 using antiviral therapies and anti-SARS-CoV-2 antibody products. The present work reports the final OP

Published
2023

15. POS1069 SYSTEMATIC LITERATURE REVIEW INFORMING THE EULAR POINTS TO CONSIDER TASK FORCE ON THE INITIATION OF TARGETED THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES AND A HISTORY OF CANCER

Author

Sebbag, E., primary, Molina Collada, J., additional, Lauper, K., additional, Aletaha, D., additional, Askling, J., additional, Benesova, K., additional, Bertheussen, H., additional, Bitoun, S., additional, Bolek, E. C., additional, Burmester, G. R., additional, Canhão, H., additional, Chatzidionysiou, K., additional, Curtis, J., additional, Danlos, F. X., additional, Guimaraes, V., additional, Hetland, M. L., additional, Iannone, F., additional, Kostine, M., additional, Kragstrup, T. W., additional, Kvien, T. K., additional, Regierer, A., additional, Schulze-Koops, H., additional, Silva-Fernández, L., additional, Szekanecz, Z., additional, Buch, M. H., additional, Finckh, A., additional, and Gottenberg, J. E., additional

Published
2023
Full Text
View/download PDF

23. AB0402 PHARMACOKINETICS AND SAFETY OF CT-P47, A PROPOSED TOCILIZUMAB BIOSIMILAR, IN COMPARISON WITH EU-APPROVED TOCILIZUMAB; A PHASE 1, RANDOMIZED, DOUBLE-BLIND, TWO-ARM, SINGLE-DOSE STUDY IN HEALTHY SUBJECTS

Author

Yu, K. S., primary, Kim, B., additional, Shin, D., additional, Park, M. K., additional, Hwang, J. G., additional, Kim, M., additional, Chung, H., additional, Ghim, J., additional, Chung, J. Y., additional, Smolen, J. S., additional, Burmester, G. R., additional, Kim, S. H., additional, Bae, Y., additional, Jeon, D., additional, Yang, G., additional, Yoo, J., additional, Bae, J., additional, and Keystone, E., additional

Published
2023
Full Text
View/download PDF

24. OP0045 EULAR POINTS TO CONSIDER ON THE INITIATION OF TARGETED THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES AND A HISTORY OF CANCER

Author

Sebbag, E., primary, Lauper, K., additional, Molina Collada, J., additional, Aletaha, D., additional, Askling, J., additional, Benesova, K., additional, Bertheussen, H., additional, Bitoun, S., additional, Bolek, E. C., additional, Burmester, G. R., additional, Canhão, H., additional, Chatzidionysiou, K., additional, Curtis, J., additional, Danlos, F. X., additional, Guimaraes, V., additional, Hetland, M. L., additional, Iannone, F., additional, Kostine, M., additional, Kragstrup, T. W., additional, Kvien, T. K., additional, Regierer, A., additional, Schulze-Koops, H., additional, Silva-Fernández, L., additional, Szekanecz, Z., additional, Buch, M. H., additional, Finckh, A., additional, and Gottenberg, J. E., additional

Published
2023
Full Text
View/download PDF

26. POS0844 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS WITH A MAXIMUM EXPOSURE OF 8.3 YEARS

Author

Winthrop, K., primary, Aletaha, D., additional, Caporali, R., additional, Tanaka, Y., additional, Takeuchi, T., additional, Van Hoek, P., additional, Stiers, P. J., additional, Rajendran, V., additional, Van Beneden, K., additional, Gottenberg, J. E., additional, and Burmester, G. R., additional

Published
2023
Full Text
View/download PDF

27. POS0540 PERFORMANCE OF COMMERCIAL SARS-COV-2 WILD-TYPE AND OMICRON BA.1 ANTIBODY ASSAYS COMPARED WITH PSEUDOVIRUS NEUTRALIZATION TESTS

Author

Habermann, E., primary, Frommert, L. M., additional, Ghannam, K., additional, Nguyen My, L., additional, Gieselmann, L., additional, Tober-Lau, P., additional, Klotsche, J., additional, Arumahandi de Silva, A. N., additional, Ten Hagen, A., additional, Zernicke, J., additional, Kurth, F., additional, Sander, L., additional, Klein, F., additional, Burmester, G. R., additional, Biesen, R., additional, and Albach, F., additional

Published
2023
Full Text
View/download PDF

28. POS0466 INTERIM UPDATE ON BASELINE CHARACTERISTICS AND EFFECTIVENESS FROM A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH FILGOTINIB (FILOSOPHY)

Author

Caporali, R., primary, Avouac, J., additional, Bevers, K., additional, Burmester, G. R., additional, Debray, T., additional, De Leonardis, F., additional, Harris, K., additional, Betteridge, N., additional, Romero-Yuste, S., additional, Verschueren, P., additional, Zignani, M., additional, and Galloway, J., additional

Published
2023
Full Text
View/download PDF

29. POS0848 DISCONTINUATION AND EFFECTIVENESS OF BARICITINIB IN RHEUMATOID ARTHRITIS ACCORDING TO PATIENT AGE AND PRIOR TREATMENT: 2-YEAR DATA FROM THE EUROPEAN COHORT OF THE RA-BE-REAL STUDY

Author

Alten, R., primary, Burmester, G. R., additional, Edwards, C. J., additional, Favalli, E. G., additional, De La Torre, I., additional, Ng, K., additional, Haladyj, E., additional, Gerwien, J., additional, Zaremba-Pechmann, L., additional, and Fautrel, B., additional

Published
2023
Full Text
View/download PDF

31. POS0229 COMBINING MTX DOES NOT RESULT IN AN ADDITIONAL EFFICACY OF UST TREATMENT IN POLYARTHRITIC PSA: SUBGROUP ANALYSIS FROM A RANDOMIZED PLACEBO-CONTROLLED INVESTIGATOR INITIATED CLINICAL TRIAL

Author

Köhm, M., primary, Foldenauer, A. C., additional, Rossmanith, T., additional, Kellner, H., additional, Kiltz, U., additional, Kleyer, A., additional, Burmester, G. R., additional, Brandt-Juergens, J., additional, Kofler, D. M., additional, Burkhardt, H., additional, and Behrens, F., additional

Published
2023
Full Text
View/download PDF

33. POS0308 LONG-TERM CLINICAL PROFILE OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA) BY CARDIOVASCULAR (CV) RISK FACTORS: A POST HOC SUBGROUP ANALYSIS

Author

Buch, M. H., primary, Gómez-Puerta, J. A., additional, Burmester, G. R., additional, Combe, B., additional, Rajendran, V., additional, Stiers, P. J., additional, Van Hoek, P., additional, Van Beneden, K., additional, Gottenberg, J. E., additional, Tanaka, Y., additional, Aletaha, D., additional, Westhovens, R., additional, and Caporali, R., additional

Published
2023
Full Text
View/download PDF

36. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNF alpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004

Author

Furst, Daniel E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Bijlsma, JWJ, Dougados, M, Emery, P, Keystone, E C, Klareskog, L, and Mease, P J

Abstract

As in previous years, the consensus group to consider the use of biological agents was constituted by rheumatologists from the Universities of Erlangen, Leiden, and Vienna in Europe in cooperation with other Universities in the USA, Canada, and Europe. Pharmaceutical industry support was obtained from a number of companies, but these institutions had no part in the decisions about the specific programme or about the academic participants at this conference. The perspective of this consensus is from the treating physician’s point of view. The 128 rheumatologists and bioscientists who attended the consensus conference were chosen from a worldwide group of physicians and other scientists from 20 countries with expertise in the use of biological agents for the treatment of rheumatic diseases. The number of attendees and participants were limited so that not everyone who might have been interested could be invited. Additional information has come to light in the past year, corroborating the major positive effect these drugs have had in rheumatoid arthritis (RA) and other rheumatic diseases, as well as further documenting adverse events. Therefore an update of the previous consensus statement1 is appropriate. The consensus statement is annotated to document the credibility of the data supporting it as much as possible. This annotation is that of Shekelle et al2 and is described in appendix 3. As the number of possible references has become so large, sometimes reviews were used and, if they contained category A references, will be referred to as category A evidence. All participants reviewed relevant clinical published articles relating to tumour necrosis factor (TNF) and interleukin (IL)-1 blocking agents. They were given a draft consensus statement and were asked to revise the document in small discussion groups; open discussion of the revisions led to a final document, representing this updated consensus statement.

Published
2004

37. The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET

Author

Talarico, R, Aguilera, S, Alexander, T, Amoura, Z, Andersen, J, Arnaud, L, Avcin, T, Marsal Barril, S, Beretta, L, Bombardieri, S, Bortoluzzi, A, Bouillot, C, Bulina, I, Burmester, G, Cannizzo, S, Cavagna, L, Chaigne, B, Cornet, A, Corti, P, Costedoat-Chalumeau, N, Davidsone, Z, Doria, A, Fenech, C, Ferraris, A, Fischer-Betz, R, Fonseca, J, Frank, C, Gaglioti, A, Galetti, I, Guimaraes, V, Hachulla, E, Holmner, M, Houssiau, F, Iaccarino, L, Jacobsen, S, Limper, M, Malfait, F, Mariette, X, Marinello, D, Martin, T, Matthews, L, Matucci-Cerinic, M, Meyer, A, Milas-Ahic, J, Moinzadeh, P, Montecucco, C, Mouthon, L, Muller-Ladner, U, Nagy, G, Patarata, E, Pileckyte, M, Pruunsild, C, Rednic, S, Romao, V, Schneider, M, Scire, C, Smith, V, Sulli, A, Tamirou, F, Tani, C, Taruscio, D, Taulaigo, A, Tincani, A, Ticciati, S, Turchetti, G, van Hagen, P, van Laar, J, Vieira, A, de Vries-Bouwstra, J, Zschocke, J, Cutolo, M, Mosca, M, Talarico R., Aguilera S., Alexander T., Amoura Z., Andersen J., Arnaud L., Avcin T., Marsal Barril S., Beretta L., Bombardieri S., Bortoluzzi A., Bouillot C., Bulina I., Burmester G. R., Cannizzo S., Cavagna L., Chaigne B., Cornet A., Corti P., Costedoat-Chalumeau N., Davidsone Z., Doria A., Fenech C., Ferraris A., Fischer-Betz R., Fonseca J. E., Frank C., Gaglioti A., Galetti I., Guimaraes V., Hachulla E., Holmner M., Houssiau F., Iaccarino L., Jacobsen S., Limper M., Malfait F., Mariette X., Marinello D., Martin T., Matthews L., Matucci-Cerinic M., Meyer A., Milas-Ahic J., Moinzadeh P., Montecucco C., Mouthon L., Muller-Ladner U., Nagy G., Patarata E., Pileckyte M., Pruunsild C., Rednic S., Romao V. C., Schneider M., Scire C. A., Smith V., Sulli A., Tamirou F., Tani C., Taruscio D., Taulaigo A. V., Tincani A., Ticciati S., Turchetti G., van Hagen P. M., van Laar J. M., Vieira A., de Vries-Bouwstra J. K., Zschocke J., Cutolo M., Mosca M., Talarico, R, Aguilera, S, Alexander, T, Amoura, Z, Andersen, J, Arnaud, L, Avcin, T, Marsal Barril, S, Beretta, L, Bombardieri, S, Bortoluzzi, A, Bouillot, C, Bulina, I, Burmester, G, Cannizzo, S, Cavagna, L, Chaigne, B, Cornet, A, Corti, P, Costedoat-Chalumeau, N, Davidsone, Z, Doria, A, Fenech, C, Ferraris, A, Fischer-Betz, R, Fonseca, J, Frank, C, Gaglioti, A, Galetti, I, Guimaraes, V, Hachulla, E, Holmner, M, Houssiau, F, Iaccarino, L, Jacobsen, S, Limper, M, Malfait, F, Mariette, X, Marinello, D, Martin, T, Matthews, L, Matucci-Cerinic, M, Meyer, A, Milas-Ahic, J, Moinzadeh, P, Montecucco, C, Mouthon, L, Muller-Ladner, U, Nagy, G, Patarata, E, Pileckyte, M, Pruunsild, C, Rednic, S, Romao, V, Schneider, M, Scire, C, Smith, V, Sulli, A, Tamirou, F, Tani, C, Taruscio, D, Taulaigo, A, Tincani, A, Ticciati, S, Turchetti, G, van Hagen, P, van Laar, J, Vieira, A, de Vries-Bouwstra, J, Zschocke, J, Cutolo, M, Mosca, M, Talarico R., Aguilera S., Alexander T., Amoura Z., Andersen J., Arnaud L., Avcin T., Marsal Barril S., Beretta L., Bombardieri S., Bortoluzzi A., Bouillot C., Bulina I., Burmester G. R., Cannizzo S., Cavagna L., Chaigne B., Cornet A., Corti P., Costedoat-Chalumeau N., Davidsone Z., Doria A., Fenech C., Ferraris A., Fischer-Betz R., Fonseca J. E., Frank C., Gaglioti A., Galetti I., Guimaraes V., Hachulla E., Holmner M., Houssiau F., Iaccarino L., Jacobsen S., Limper M., Malfait F., Mariette X., Marinello D., Martin T., Matthews L., Matucci-Cerinic M., Meyer A., Milas-Ahic J., Moinzadeh P., Montecucco C., Mouthon L., Muller-Ladner U., Nagy G., Patarata E., Pileckyte M., Pruunsild C., Rednic S., Romao V. C., Schneider M., Scire C. A., Smith V., Sulli A., Tamirou F., Tani C., Taruscio D., Taulaigo A. V., Tincani A., Ticciati S., Turchetti G., van Hagen P. M., van Laar J. M., Vieira A., de Vries-Bouwstra J. K., Zschocke J., Cutolo M., and Mosca M.

Abstract

In order to address the main challenges related to the rare diseases (RDs) the European Commission launched the European Reference Networks (ERNs), virtual networks involving healthcare providers (HCPs) across Europe. The mission of the ERNs is to tackle low prevalence and RDs that require highly specialised treatment and a concentration of knowledge and resources. In fact, ERNs offer the potential to give patients and healthcare professionals across the EU access to the best expertise and timely exchange of lifesaving knowledge, trying to make the knowledge travelling more than patients. For this reason, ERNs were established as concrete European infrastructures, and this is particularly crucial in the framework of rare and complex diseases in which no country alone has the whole knowledge and capacity to treat all types of patients. It has been five years since their kick-off launch in Vilnius in 2017. The 24 ERNs have been intensively working on different transversal areas, including patient management, education, clinical practice guidelines, patients' care pathways and many other fundamental topics. The present work is therefore aimed not only at reporting a summary of the main activities and milestones reached so far, but also at celebrating the first 5 years of the ERN on Rare and Complex Connective Tissue and Musculo-skeletal Diseases (ReCONNET), in which the members of the network built together one of the 24 infrastructures that are hopefully going to change the scenario of rare diseases across the EU.

Published
2022

40. Sicherheit und Wirksamkeitshinweise zum Off-label-Einsatz von Biologikatherapien nach Versagen konventioneller Therapien bei Patienten mit entzündlich rheumatischen Erkrankungen: Ergebnisse eines nationalen Registers (GRAID2)

Author

Proft, F., Schulze-Koops, H., Grunke, M., Schrezenmeier, E., Halleck, F., Henes, J., Unger, L., Schmidt, E., Fiehn, C., Jacobi, A., Iking-Konert, C., Kneitz, C., Schmidt, R. E., Bannert, B., Voll, R. E., Fischer-Betz, R., Kötter, I., Tony, H. P., Holle, J., Aringer, M., Erler, A., Behrens, F., Burmester, G. R., and Dörner, T.

Published
2018
Full Text
View/download PDF

41. Expanded ILC2s in human infant intestines promote tissue-growth

Author

Möller, KJ, primary, Wegner, LHM, additional, Malsy, J, additional, Baumdick, ME, additional, Borggrewe, M, additional, Jordan-Paiz, A, additional, Jung, JM, additional, Martrus, G, additional, Kretschmer, P, additional, Sagebiel, AF, additional, Schreurs, RRCE, additional, Hagen, SH, additional, Burmester, G, additional, Clauditz, TS, additional, Pals, ST, additional, Boettcher, M, additional, Melling, N, additional, Sauter, G, additional, Tomuschat, C, additional, Königs, I, additional, Schumacher, U, additional, Altfeld, M, additional, Bernink, JH, additional, Perez, D, additional, Reinshagen, K, additional, and Bunders, MJ, additional

Published
2023
Full Text
View/download PDF

42. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

Author

Talarico, Rosaria R., Ramirez, G. A., Barreira, S. C., Cardamone, C., Triggianese, P., Aguilera, S., Andersen, J., Avcin, T., Benistan, K., Bertsias, G., Bortoluzzi, A., Bouillot, C., Bulina, I., Burmester, G. R., Callens, S., Carreira, P. E., Cervera, R., Cutolo, M., Damian, L., Torre, E. Della, Faria, R., Fonseca, J. E., Galetti, I., Hachulla, E., Iaccarino, L., Jacobsen, S., Khmelinskii, N., Limper, M., Marinello, D., Meyer, A., Moroncini, G., Nagy, G., Olesinska, M., Pamfil, C., Pileckyte, M., Pistello, M., Rednic, S., Richez, C., Romão, V. C., Schneider, M., Sciascia, S., Scirè, C. A., Simonini, G., Smith, V., Sulli, A., Tani, C., Tas, S. W., Tincani, A., Vonk, M. C., Tektonidou, M., Mosca, M., Talarico, Rosaria R., Ramirez, G. A., Barreira, S. C., Cardamone, C., Triggianese, P., Aguilera, S., Andersen, J., Avcin, T., Benistan, K., Bertsias, G., Bortoluzzi, A., Bouillot, C., Bulina, I., Burmester, G. R., Callens, S., Carreira, P. E., Cervera, R., Cutolo, M., Damian, L., Torre, E. Della, Faria, R., Fonseca, J. E., Galetti, I., Hachulla, E., Iaccarino, L., Jacobsen, S., Khmelinskii, N., Limper, M., Marinello, D., Meyer, A., Moroncini, G., Nagy, G., Olesinska, M., Pamfil, C., Pileckyte, M., Pistello, M., Rednic, S., Richez, C., Romão, V. C., Schneider, M., Sciascia, S., Scirè, C. A., Simonini, G., Smith, V., Sulli, A., Tani, C., Tas, S. W., Tincani, A., Vonk, M. C., Tektonidou, M., and Mosca, M.

Abstract

Recent studies have shown that people who are immunocompromised may inadvertently play a role in spurring the mutations of the virus that create new variants. This is because some immunocompromised individuals remain at risk of getting COVID-19 despite vaccination, experience more severe disease, are susceptible to being chronically infected and remain contagious for longer if they become infected and considering that immunocompromised individuals represent approximately 2% of the overall population, this aspect should be carefully considered. So far, some autoimmune rheumatic disease (ARD) patients with COVID-19 have been treated with antiviral therapies or anti-SARS-CoV-2 antibody products. However, there is no homogeneous approach to these treatment strategies. This issue was addressed within the European Reference Network (ERN) on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ReCONNET) in a discussion among experts and patient’s representatives in the context of the rare and complex connective tissue diseases (rCTDs) covered by the Network. ERN ReCONNET is one of the 24 ERNs launched by the European Commission in 2017 with the aim of tackling low prevalence and rare diseases that require highly specialised treatment and promoting concentration of knowledge and resources through virtual networks involving healthcare providers (HCPs) across the European Union (EU). Considering the urgent need to provide guidance not only to the rCTDs community, but also to the whole ARDs community, a multidisciplinary Task Force, including expert clinicians and European Patient Advocacy Group (ePAG) Advocates, was created in the framework of ERN ReCONNET with the aim of developing overarching principles (OP) and points-to-consider (PtC) on a homogenous approach to treat immunocompromised patients with ARDs (with a particular focus on CTDs) affected by COVID-19 using antiviral therapies and anti-SARS-CoV-2 antibody products. The present work reports the final OP, Recent studies have shown that people who are immunocompromised may inadvertently play a role in spurring the mutations of the virus that create new variants. This is because some immunocompromised individuals remain at risk of getting COVID-19 despite vaccination, experience more severe disease, are susceptible to being chronically infected and remain contagious for longer if they become infected and considering that immunocompromised individuals represent approximately 2% of the overall population, this aspect should be carefully considered. So far, some autoimmune rheumatic disease (ARD) patients with COVID-19 have been treated with antiviral therapies or anti-SARS-CoV-2 antibody products. However, there is no homogeneous approach to these treatment strategies. This issue was addressed within the European Reference Network (ERN) on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ReCONNET) in a discussion among experts and patient's representatives in the context of the rare and complex connective tissue diseases (rCTDs) covered by the Network. ERN ReCONNET is one of the 24 ERNs launched by the European Commission in 2017 with the aim of tackling low prevalence and rare diseases that require highly specialised treatment and promoting concentration of knowledge and resources through virtual networks involving healthcare providers (HCPs) across the European Union (EU). Considering the urgent need to provide guidance not only to the rCTDs community, but also to the whole ARDs community, a multidisciplinary Task Force, including expert clinicians and European Patient Advocacy Group (ePAG) Advocates, was created in the framework of ERN ReCONNET with the aim of developing overarching principles (OP) and points-to-consider (PtC) on a homogenous approach to treat immunocompromised patients with ARDs (with a particular focus on CTDs) affected by COVID-19 using antiviral therapies and anti-SARS-CoV-2 antibody products. The present work reports the final

Published
2023

46. Mise à jour de l’analyse intégrée de la tolérance du filgotinib (FIL) chez les patients atteints de polyarthrite rhumatoïde (PR) active modérée à sévère recevant un traitement (TT) sur une période médiane de 2,2 ans

Author

Gottenberg, J.E., primary, Winthrop, K., additional, Tanaka, Y., additional, Takeuchi, T., additional, Burmester, G.R., additional, Kivitz, A., additional, Genovese, M.C., additional, Pechonkina, A., additional, Matzkies, F., additional, Bartok, B., additional, Chen, K., additional, Jiang, D., additional, Tiamiyu, I., additional, Besuyen, R., additional, Strengholt, S., additional, and Burmester, G., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results